ScholarIQanswers from OpenAlex & ORCID
Per Pfeiffer
ResearcherPublications, citations & collaboration network
Per Pfeiffer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Per Pfeiffer have?
ScholarIQindexed works
Per Pfeiffer has 547 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Per Pfeiffer have?
ScholarIQcitation count
Per Pfeiffer has 22,165 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Per Pfeiffer?
ScholarIQh-index
Per Pfeiffer has an h-index of 60 in OpenAlex.
What is the i10-index of Per Pfeiffer?
ScholarIQi10-index
Per Pfeiffer has an i10-index of 205 in OpenAlex.
What is the ORCID of Per Pfeiffer?
ScholarIQorcid
The ORCID for Per Pfeiffer is on the source record.
What is the OpenAlex record for Per Pfeiffer?
ScholarIQopenalex
The OpenAlex for Per Pfeiffer is on the source record.
What are the most-cited papers on Per Pfeiffer?
ScholarIQmost cited works
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T. Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent‐Puig, Frédérique Penault–Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric FIORE, Alice Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten, Corrie A.M. Marijnen, Hein Putter, Elma Meershoek‐Klein Kranenbarg, Annet G.H. Roodvoets, Irıs D. Nagtegaal, Regina G. H. Beets‐Tan, Lennart K. Blomqvist, Tone Fokstuen, Albert J. ten Tije, Jaume Capdevila, Mathijs P. Hendriks, Ibrahim Edhemović, Andrés Cervantes, Per J. Nilsson, Bengt Glimelius, Cornelis J.�H. van de Velde, Geke A.P. Hospers, Lars Østergaard, Frank Svendsen Jensen, Per Pfeiffer, K.E.J. Jensen, Mathijs P. Hendriks, Wilhelmina H. Schreurs, H.P. Knol, J.J. van der Vliet, Jurriaan B. Tuynman, A. Bruynzeel, Emile D. Kerver, Sebastiaan Festen, Monique E. van Leerdam, Geerard L. Beets, L. Dewit, C.J.A. Punt, Pieter J. Tanis, Elisabeth D. Geijsen, Peter Nieboer, Wim Bleeker, Albert J. ten Tije, Rogier M. P. H. Crolla, Addy C.M. van de Luijtgaarden, Jan Willem T. Dekker, J.M. Immink, Frank J. Jeurissen, Andreas Marinelli, Heleen M. Ceha, Tanja C. Stam, P. Quarles an Ufford, Willem H. Steup, Alex L.T. Imholz, R.J.I. Bosker, Jasper Bekker, G.J. Creemers, Grard A. P. Nieuwenhuijzen, Henk van den Berg, Wendy M. van der Deure, Roderick F. Schmitz, Johan M. van Rooijen, Annette F. T. Olieman, A.C.M. van den Bergh, Derk Jan A. de Groot, Klaas Havenga, Jannet C. Beukema, Jacob D. de Boer, Peter H.J.M. Veldman, Ester Siemerink, J.W.P. Vanstiphout, B. De Valk, Q. A. J. Eijsbouts, M. Polée, Christiaan Hoff, Annerie Slot, H.W. Kapiteijn, Koen Peeters, Femke P. Peters, P.A. Nijenhuis, Sandra A. Radema, Hans De Wilt, Pètra M. Braam, G.J. Veldhuis, Daniël A. Hess, Tom Rozema, O. Reerink, Daan ten Bokkel Huinink, A. Pronk, Josephine M. I. Vos, Metin Tascilar, Gijs A. Patijn, Christian Kersten, Odd Mjåland, Marianne G. Guren, Arild Nesbakken, Janez Benedik, Ibrahim Edhemović, Vaneja Velenik, Jaume Capdevila, Eloy Espín, Ramón Salazar
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Sun Young Rha, Sun Young Rha, Do-Youn Oh, Patricio Yañez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel González Fernández, Jin Li, Maeve A Lowery, Timuçin Çil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S Wyrwicz, Guillermo Méndez, Juan Manuel O’Connor, Alvaro Yanzi Castilla, Juan Cundom, Diego Kaen, Rachel Wong, Weng Ng, Morteza Aghmesheh, Mauricio Peressoni, Carlos Eduardo Mattos da Cunha Andrade, Fábio Franke, Gustavo R. Alves, Felipe Jose Cruz, Karina Vianna, Maria Marcela Monteiro, Michael J. Raphael, Scott Berry, Raymond Woo-Jun Jang, Ann Tan, Jamil Asselah, Patricio Yañez Weber, Mauricio Mahave, César Sánchez, Pamela Salman, Yuxian Bai, Jin Li, Xiaochun Zhang, Tianshu Liu, Xiaoyan Lin, Shukui Qin, Jianwei Yang, Suxia Luo, Wěi Li, Jieer Ying, Xi Chen, Shan Zeng, Yanli Qu, Lin Yang, Lin Zhao, Ping Chen, Hongming Pan, Enxiao Li, Feng Ye, Jianwei Lu, Xinjun Liang, Qun Zhao, Xianli Yin, Junhe Li, Ling Yang, Guoqing Lv, Shouguo Li, Álvaro Guerrero, Juan Rubiano, Manuel Gonzalez Fernandez, Ray Manneh Kopp, Adrián Guzmán Ramírez, Luis Corrales, Ileana Gonzalez Herrera, Bohuslav Melichar, Tomáš Büchler, Tomáš Svoboda, Radka Obermannová, David Vrána, Jakub Cvek, Per Pfeiffer, Lene Bæksgaard, Mette Yilmaz, Valérie Boige, Daniel López‐Trabada, Christophe Borg, Diane Pannier, Sandrine Hiret, Frédéric Di Fiore, Jean‐Philippe Metges, Dirk Arnold, Uwe M. Martens
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Thierry Conroy, Per Pfeiffer, Valérie Vilgrain, Ángela Lamarca, Thomas Seufferlein, Eileen M. O’Reilly, Thilo Hackert, Talia Golan, Gerald W. Prager, Karin Haustermans, Arndt Vogel, Michel Ducreux